Human testing has yet to be announced
In search of ways to complement jabs or to treat patients who can’t be vaccinated, scientists have tested inhalable anti-Covid nanobodies on hamsters, saying they’re effective in fighting the virus by targeting its spike protein.
The promising new findings came courtesy of researchers from the University of Pittsburgh School of Medicine, marking the first time nanobodies have been tested for inhalation treatment of the coronavirus disease.
Nanobodies are similar to monoclonal antibodies, widely used in certain cancer treatments, but are smaller in size and boast a lower cost of production, which may prove key to a global rollout should the treatment gain regulatory approval in future.
In a new paper published in @ScienceAdvances, researchers from @PittTweet showed that inhalable nanobodies targeting the spike protein of the SARS-CoV-2 coronavirus can prevent and treat severe #COVID19 in hamsters. https://t.co/jbsJ0H5clypic.twitter.com/PcgKjjMdEF— UPMC (@UPMCnews) May 27, 2021
The researchers previously identified…
View original post 318 more words